A Comprehensive Review on Breast Cancer

A Comprehensive Review on Breast Cancer 

Shubham Kumar Singh, Aditya Rai

SFS College of pharmacy, Rasra, Ballia, U.P, India

Abstract

Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Its complex molecular heterogeneity, diverse clinical presentation, and therapeutic resistance continue to pose significant challenges to effective disease management. Advances in molecular biology and precision oncology have substantially improved the understanding of breast cancer pathogenesis, enabling earlier diagnosis and the development of personalized treatment strategies. This review summarizes the current knowledge on breast cancer, including its epidemiology, anatomy and biology, etiological factors, molecular pathogenesis, diagnostic approaches, and clinically relevant biomarkers. It further discusses established therapeutic modalities, including surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy, while highlighting recent advances in antibody-drug conjugates, PARP inhibitors, nanotechnology-based drug delivery systems, artificial intelligence, and precision medicine. These emerging therapeutic approaches have demonstrated considerable potential in improving treatment efficacy, reducing systemic toxicity, and overcoming drug resistance. Despite these advances, tumor heterogeneity, metastatic progression, and treatment resistance remain major barriers to achieving optimal clinical outcomes. Continued research focusing on biomarker discovery, molecular profiling, and innovative therapeutic strategies is essential for advancing personalized breast cancer management and improving patient survival and quality of life.

Keywords: Breast cancer, liposomes, combination therapy, drug delivery, nanotechnology

Corresponding Author

Shubham Kumar Singh

Received: 01/05/2026

Revised: 20/06/2026

Accepted: 25/07/2026

DOI: http://doi.org/10.66204/GJPSR-1187-2026-2-8-2

Copyright Information 

© 2026 The Authors. This article is published by Global Journal of Pharmaceutical and Scientific Research 

How to Cite

Singh SK, Rai A. A Comprehensive Review on Breast Cancer. Global Journal of Pharmaceutical and Scientific Research. 2026; 2(8):1187-1216. ISSN: 3108-0103. http://doi.org/10.66204/GJPSR-1187-2026-2-8-2.

  1. INTRODUCTION

Breast cancer is the most frequently diagnosed malignancy among women and remains one of the leading causes of cancer-related morbidity and mortality worldwide. Despite remarkable advances in early detection, molecular diagnostics, and personalized therapeutic approaches, breast cancer continues to pose a significant public health challenge because of its heterogeneous biological characteristics, variable clinical behavior, and complex mechanisms underlying disease progression. Wilkinson et al. (2022) reported that breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally, emphasizing the urgent need for effective prevention strategies, early diagnosis, and individualized treatment approaches. Furthermore, the increasing incidence observed in both developed and developing countries highlights the growing global healthcare burden associated with this disease.

Breast cancer is no longer considered a single disease entity but rather a heterogeneous group of malignancies characterized by distinct histopathological, molecular, and genetic profiles. Advances in molecular biology and genomics have significantly enhanced the understanding of breast cancer pathogenesis, enabling classification into clinically relevant molecular subtypes, including Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancer (TNBC). Xiong et al. (2025) demonstrated that these molecular classifications have substantially improved disease characterization and facilitate personalized therapeutic decision-making. Similarly, Popa et al. (2025) emphasized that molecular heterogeneity is one of the principal determinants of tumor aggressiveness, therapeutic response, recurrence, and overall patient prognosis.

The management of breast cancer has evolved considerably over the past two decades through the adoption of multidisciplinary treatment strategies. Conventional therapeutic modalities, including surgery, radiotherapy, chemotherapy, endocrine therapy, and targeted therapy, continue to constitute the foundation of clinical management. More recently, advances in precision oncology have introduced novel treatment options such as antibody-drug conjugates, immune checkpoint inhibitors, cyclin-dependent kinase (CDK) 4/6 inhibitors, PARP inhibitors, and phosphoinositide 3-kinase (PI3K) inhibitors, which have significantly improved survival outcomes in selected patient populations. According to Huppert et al. (2023), biomarker-driven treatment selection has become an integral component of breast cancer management, enabling clinicians to optimize therapeutic efficacy while minimizing treatment-related toxicity.

Despite these remarkable therapeutic advancements, breast cancer continues to present several clinical challenges. Tumor heterogeneity, intrinsic and acquired drug resistance, metastatic dissemination, treatment-associated adverse effects, and disparities in healthcare accessibility remain major obstacles to achieving favorable long-term clinical outcomes. Li et al. (2022) reported that treatment resistance remains one of the primary reasons for disease recurrence and poor prognosis, particularly among patients diagnosed with aggressive subtypes such as triple-negative and metastatic breast cancer. Moreover, changing reproductive patterns, increasing obesity, sedentary lifestyles, prolonged hormonal exposure, environmental risk factors, and inherited genetic mutations have collectively contributed to the rising incidence of breast cancer among younger women across different populations.

Recent advances in molecular diagnostics, genomics, proteomics, liquid biopsy, single-cell sequencing, spatial transcriptomics, artificial intelligence, and nanotechnology-based drug delivery systems are transforming the landscape of breast cancer diagnosis and treatment. These innovative technologies offer new opportunities for early disease detection, comprehensive molecular profiling, therapeutic response prediction, and personalized treatment planning. Subhan et al. (2023) highlighted that precision medicine, supported by molecular profiling and biomarker-guided therapy, is expected to redefine future breast cancer management by enabling individualized therapeutic interventions. Furthermore, nanotechnology-based drug delivery systems have shown considerable promise in enhancing drug bioavailability, improving tumor-specific targeting, reducing systemic toxicity, and overcoming multidrug resistance, thereby improving therapeutic outcomes.

Considering the rapid expansion of knowledge regarding breast cancer biology and the continuous development of innovative diagnostic and therapeutic approaches, an updated and comprehensive review is warranted. Therefore, the present review critically discusses the epidemiology, risk factors, molecular pathogenesis, histopathological and molecular classification, diagnostic approaches, prognostic biomarkers, conventional and emerging therapeutic strategies, mechanisms of drug resistance, nanotechnology-based drug delivery systems, precision oncology, and future perspectives in breast cancer management. By integrating recent evidence from basic, translational, and clinical research, this review aims to provide clinicians, oncologists, pharmaceutical scientists, and researchers with a comprehensive understanding of current advances and future directions in breast cancer diagnosis and treatment.

2. Global Epidemiology and Disease Burden

Breast cancer is the most frequently diagnosed cancer among women and remains a major contributor to global cancer-related morbidity and mortality. Over the past several decades, its incidence has increased steadily across both developed and developing countries, making it one of the most significant public health challenges worldwide. This growing burden is primarily attributed to demographic changes, population ageing, urbanization, lifestyle modifications, and improvements in cancer detection and registration systems. Bray et al. (2024) reported that breast cancer accounts for approximately one in every eight newly diagnosed cancer cases globally, emphasizing its considerable impact on healthcare systems and national cancer control programs.

Recent estimates from the Global Cancer Observatory (GLOBOCAN) indicate that breast cancer continues to be the most commonly diagnosed malignancy among women worldwide, with more than 2.3 million new cases diagnosed annually, representing nearly 12% of all newly diagnosed cancers. In addition, breast cancer remains one of the leading causes of cancer-related deaths among women, accounting for approximately 670,000 deaths each year. Although survival rates have improved considerably in many high-income countries because of advances in screening, diagnosis, and treatment, mortality remains disproportionately high in low- and middle-income countries where healthcare resources are limited (Ferlay et al., 2024).

The geographical distribution of breast cancer demonstrates remarkable regional variation. Countries with high Human Development Index (HDI) generally report higher incidence rates owing to increased life expectancy, delayed childbearing, reduced fertility, obesity, physical inactivity, alcohol consumption, and greater participation in organized mammographic screening programs. In contrast, many developing nations experience comparatively lower incidence but significantly higher mortality because patients frequently present with advanced-stage disease and have limited access to specialized oncology services. Heer et al. (2020) observed that socioeconomic inequalities, inadequate healthcare infrastructure, and delayed diagnosis remain the principal determinants of poor survival outcomes in resource-limited settings.

Breast cancer has emerged as the leading cancer affecting women in India, surpassing cervical cancer over the past decade. Rapid urbanization, westernization of lifestyle, increasing prevalence of obesity, declining breastfeeding practices, delayed age at first childbirth, and hormonal factors have collectively contributed to the increasing incidence of the disease. Furthermore, Indian women are often diagnosed at a younger age compared with women in Western countries and are more likely to present with locally advanced or metastatic disease. According to Malvia et al. (2017), limited awareness regarding breast self-examination, inadequate population-based screening programs, social stigma, and disparities in healthcare accessibility continue to delay diagnosis and adversely affect treatment outcomes in India.

Age is one of the strongest non-modifiable risk factors associated with breast cancer. The incidence rises progressively after the age of 50 years, particularly among postmenopausal women. Nevertheless, recent epidemiological studies have demonstrated an increasing occurrence of breast cancer in younger women, highlighting the influence of reproductive patterns, obesity, environmental exposures, and inherited genetic susceptibility. Lei et al. (2021) suggested that changes in lifestyle behaviours and metabolic risk factors are contributing to the shifting epidemiological profile of breast cancer, particularly in rapidly developing nations.

The economic burden associated with breast cancer extends far beyond direct medical expenses. Long-term treatment, repeated hospitalizations, targeted therapies, supportive care, rehabilitation, and productivity loss impose substantial financial pressure on patients, families, and healthcare systems. In addition, psychosocial consequences, including anxiety, depression, impaired quality of life, and reduced work productivity, further amplify the overall disease burden. Consequently, strengthening national cancer control programs through public awareness initiatives, organized screening strategies, timely diagnosis, equitable access to evidence-based treatment, and survivorship care has become a global healthcare priority.

  3. Anatomy and Biology of the Normal Breast

The mammary gland is a specialized exocrine organ that undergoes continuous structural and functional modifications throughout different stages of life. Unlike many other organs, the breast develops primarily after birth and remains highly responsive to hormonal fluctuations during puberty, pregnancy, lactation, and menopause. These physiological changes are tightly regulated by endocrine and paracrine signaling pathways that coordinate epithelial proliferation, differentiation, and tissue remodeling. Since the majority of breast malignancies arise from the epithelial components of the mammary gland, understanding normal breast anatomy and biology provides the foundation for elucidating the mechanisms involved in breast carcinogenesis. Macias and Hinck (2012) emphasized that normal mammary gland development depends on the coordinated interaction between epithelial cells, stromal tissues, extracellular matrix components, and endocrine hormones, while disruption of these interactions contributes to malignant transformation.

3.1 Gross Anatomy of the Breast

The adult female breast is located on the anterior chest wall, extending from the second to the sixth rib and from the lateral border of the sternum to the mid-axillary line. Although breast size and shape vary considerably among individuals, the internal anatomical organization remains relatively constant. Each breast consists of glandular tissue, adipose tissue, fibrous connective tissue, blood vessels, lymphatics, and peripheral nerves that function together to support lactation and maintain tissue homeostasis.

The glandular component is divided into approximately 15-20 lobes, each connected to the nipple through an independent lactiferous duct. Every lobe is further subdivided into smaller lobules containing clusters of secretory alveoli responsible for milk synthesis during lactation. Between these glandular structures lies adipose tissue, which determines breast volume and provides mechanical support. Dense fibrous connective tissue, commonly known as Cooper's ligaments, extends throughout the breast parenchyma to maintain structural integrity and suspend the breast against gravity. Rusby et al. (2020) reported that although adipose tissue primarily contributes to breast morphology, the glandular compartment is responsible for the physiological functions of the mammary gland and represents the principal site of neoplastic transformation.

3.2 Histological Organization of the Mammary Gland

Microscopically, the breast is composed of a highly organized branching ductal system terminating in terminal ductal-lobular units (TDLUs), which serve as the primary functional units of the mammary gland. Each TDLU consists of terminal ducts and multiple secretory acini lined by two distinct epithelial layers. The inner luminal epithelial cells are responsible for milk production and secretion, whereas the outer myoepithelial cells possess contractile properties that facilitate milk ejection during lactation.

Surrounding the epithelial compartment is a specialized basement membrane that separates epithelial cells from the underlying stromal tissue. The stromal compartment comprises fibroblasts, adipocytes, endothelial cells, immune cells, extracellular matrix proteins, and vascular networks that collectively regulate tissue architecture and cellular communication. The integrity of the basement membrane and epithelial-stromal interactions is essential for maintaining normal tissue organization. Loss of these structural barriers represents one of the earliest events during the progression from in situ carcinoma to invasive breast cancer. Visvader (2011) suggested that alterations within the terminal ductal-lobular unit provide the initial microenvironment for breast tumor initiation.

3.3 Cellular Composition and Mammary Stem Cells

The mammary epithelium contains a heterogeneous population of differentiated cells and tissue-resident stem cells that ensure continuous tissue renewal throughout adult life. Mammary stem cells possess the capacity for self-renewal and multilineage differentiation, allowing regeneration of both luminal and myoepithelial cell populations during normal development and pregnancy. Under physiological conditions, cellular proliferation is tightly controlled by signaling pathways that regulate stem cell maintenance, differentiation, and apoptosis.

Recent molecular studies have demonstrated that abnormalities affecting mammary stem cells or lineage-restricted progenitor cells may initiate breast carcinogenesis. Genetic mutations, epigenetic alterations, and dysregulated signaling pathways can transform these long-lived cells into tumor-initiating cells capable of sustained proliferation and metastatic dissemination. Fu et al. (2023) highlighted that mammary stem cells contribute significantly to intratumoral heterogeneity, therapeutic resistance, and disease recurrence, making them important targets for future anticancer therapies.

3.4 Hormonal Regulation of Breast Development

Breast development and physiological function are predominantly regulated by ovarian and pituitary hormones. During puberty, estrogen stimulates elongation and branching of the ductal network, while progesterone promotes the formation and maturation of lobuloalveolar structures. Pregnancy induces extensive epithelial proliferation and differentiation under the combined influence of estrogen, progesterone, prolactin, placental lactogen, and growth hormone, preparing the mammary gland for milk production.

Following parturition, prolactin stimulates milk synthesis within secretory epithelial cells, whereas oxytocin induces contraction of surrounding myoepithelial cells, facilitating milk ejection through the ductal system. After menopause, declining estrogen concentrations lead to gradual involution of glandular tissue, accompanied by increased deposition of adipose and fibrous tissue. Brisken and Ataca (2015) reported that prolonged exposure to endogenous or exogenous estrogen increases epithelial cell proliferation and may enhance the accumulation of oncogenic mutations, thereby increasing breast cancer susceptibility.

3.5 Breast Microenvironment

The mammary gland exists within a highly dynamic tissue microenvironment comprising fibroblasts, adipocytes, immune cells, endothelial cells, extracellular matrix proteins, and soluble growth factors. These components establish reciprocal communication with mammary epithelial cells through cytokines, chemokines, hormones, and extracellular matrix remodeling enzymes, thereby regulating tissue development, wound healing, immune surveillance, and angiogenesis.

During malignant transformation, the physiological balance between epithelial and stromal compartments becomes disrupted. Activated fibroblasts, inflammatory cells, tumor-associated macrophages, and altered extracellular matrix components collectively promote tumor growth, angiogenesis, immune evasion, and metastatic dissemination. Increasing evidence indicates that the tumor microenvironment actively participates in breast cancer progression rather than merely providing structural support. Bissell and Hines (2011) emphasized that reciprocal interactions between epithelial cells and the surrounding stroma are fundamental determinants of both normal mammary gland biology and breast cancer development.

3.6 Vascular and Lymphatic Supply

The breast receives its arterial blood supply primarily from the internal thoracic artery, lateral thoracic artery, thoracoacromial artery, and posterior intercostal arteries. Venous drainage generally parallels the arterial circulation, ensuring efficient removal of metabolic waste products and maintaining tissue viability.

Lymphatic drainage plays a particularly important role in breast cancer because it represents the principal pathway for regional metastatic spread. Approximately 75% of breast lymph drains into the axillary lymph nodes, while the remaining lymphatic drainage occurs through the internal mammary, supraclavicular, and interpectoral lymph node chains. Assessment of axillary lymph node involvement remains one of the most important prognostic indicators in breast cancer staging and therapeutic planning. Consequently, sentinel lymph node biopsy has become the preferred surgical procedure for evaluating regional lymphatic metastasis while minimizing postoperative complications. Giuliano et al. (2023) demonstrated that sentinel lymph node mapping provides accurate staging information with significantly lower morbidity than conventional axillary lymph node dissection. 

4. Etiology and Risk Factors

Breast cancer is a multifactorial disease resulting from the complex interaction of genetic susceptibility, hormonal influences, environmental exposures, lifestyle factors, and aging. Unlike hereditary cancers caused by single-gene mutations, most breast cancers arise sporadically through the gradual accumulation of genetic and epigenetic alterations that disrupt normal cellular homeostasis. These alterations affect key biological processes including cell-cycle regulation, DNA repair, apoptosis, angiogenesis, and immune surveillance, ultimately leading to uncontrolled cellular proliferation and malignant transformation. Harbeck et al. (2019) emphasized that breast cancer develops through a multistep process involving interactions between inherited predisposition and acquired environmental and hormonal risk factors. Although several determinants have been identified, the contribution of each factor varies among individuals, reflecting the heterogeneous nature of the disease.

4.1 Genetic Risk Factors

Genetic predisposition is one of the most important non-modifiable determinants of breast cancer susceptibility. Approximately 5-10% of all breast cancers are hereditary and are primarily associated with germline pathogenic variants in high-penetrance susceptibility genes. Among these, mutations in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancer syndromes. These genes encode proteins essential for homologous recombination-mediated DNA repair, and loss of their function leads to genomic instability and accumulation of oncogenic mutations. Women carrying pathogenic BRCA1 or BRCA2 mutations have a markedly increased lifetime risk of developing breast cancer compared with the general population. Sokolova et al. (2023) reported that BRCA1-associated tumors are frequently triple-negative, whereas BRCA2 mutations are more commonly associated with hormone receptor-positive breast cancers.

Beyond BRCA genes, several additional susceptibility genes have been implicated in hereditary breast cancer. Germline mutations in TP53, PALB2, CHEK2, ATM, PTEN, and CDH1 also increase disease susceptibility by impairing DNA damage response, cell-cycle regulation, or tumor suppressor pathways. Although these mutations occur less frequently, they contribute significantly to familial breast cancer risk and have important implications for genetic counseling, cancer surveillance, and individualized therapeutic strategies. Recent advances in next-generation sequencing have facilitated the identification of moderate-risk susceptibility genes, thereby improving hereditary cancer risk assessment and personalized clinical management (Tung et al., 2020).

4.2 Hormonal and Reproductive Factors

Hormonal exposure plays a central role in breast carcinogenesis because mammary epithelial cells are highly responsive to estrogen and progesterone. Prolonged exposure to endogenous estrogens stimulates repeated cycles of epithelial proliferation, thereby increasing the likelihood of DNA replication errors and accumulation of oncogenic mutations. Consequently, reproductive factors that extend a woman's cumulative hormonal exposure significantly influence breast cancer risk.

Early menarche, late menopause, nulliparity, delayed first full-term pregnancy, and reduced breastfeeding duration have consistently been associated with an increased risk of hormone receptor-positive breast cancer. Conversely, early childbirth and prolonged breastfeeding exert protective effects by promoting terminal differentiation of mammary epithelial cells and reducing lifetime estrogen exposure. In addition, postmenopausal hormone replacement therapy, particularly combined estrogen-progestin therapy, has been associated with an elevated incidence of breast cancer following long-term use. Collaborative Group on Hormonal Factors in Breast Cancer (2019) demonstrated that reproductive history and exogenous hormone exposure substantially influence breast cancer risk across different populations.

4.3 Lifestyle and Metabolic Risk Factors

Lifestyle-related factors contribute significantly to the increasing global incidence of breast cancer and represent important targets for disease prevention. Obesity, particularly after menopause, has emerged as one of the strongest modifiable risk factors. Increased adipose tissue enhances peripheral conversion of androgens to estrogen through aromatase activity while simultaneously promoting chronic inflammation, insulin resistance, and altered adipokine secretion, thereby creating a pro-tumorigenic microenvironment. Lauby-Secretan et al. (2016) identified excess body weight as a major contributor to postmenopausal breast cancer.

Physical inactivity further amplifies disease risk through its adverse effects on obesity, insulin sensitivity, and systemic inflammation. Numerous epidemiological studies have demonstrated that regular physical activity lowers breast cancer risk by improving metabolic homeostasis, reducing circulating estrogen concentrations, and enhancing immune function. Similarly, alcohol consumption has been consistently associated with an increased incidence of breast cancer through mechanisms involving oxidative stress, estrogen metabolism, and DNA damage. In contrast, adherence to healthy dietary patterns rich in fruits, vegetables, whole grains, and omega-3 fatty acids has been associated with modest reductions in breast cancer risk (World Cancer Research Fund/American Institute for Cancer Research, 2018).

4.4 Environmental and Occupational Risk Factors

Environmental exposures also contribute to breast cancer development, although their individual effects are often less pronounced than those of genetic or hormonal factors. Ionizing radiation remains one of the most well-established environmental carcinogens, particularly when exposure occurs during childhood or adolescence, a period characterized by rapid mammary gland development. Survivors of childhood cancers treated with chest irradiation exhibit a substantially increased lifetime risk of developing breast cancer.

Growing attention has also focused on endocrine-disrupting chemicals, including bisphenol A (BPA), phthalates, polychlorinated biphenyls (PCBs), and certain pesticides, which may interfere with estrogen signaling and mammary gland development. Although experimental studies suggest a potential role for these compounds in breast carcinogenesis, epidemiological evidence remains inconclusive, and further investigation is required. Predieri et al. (2022) emphasized that chronic exposure to endocrine-disrupting chemicals may influence hormonal regulation and increase susceptibility to hormone-dependent malignancies.

4.5 Age, Breast Density, and Previous Benign Breast Disease

Increasing age remains the strongest independent risk factor for breast cancer. The majority of cases occur after 50 years of age, reflecting the cumulative accumulation of somatic mutations and age-related declines in genomic stability. Nevertheless, recent epidemiological studies indicate an increasing incidence among younger women, suggesting that additional genetic, environmental, and lifestyle factors are modifying traditional age-related disease patterns.

Mammographic breast density has also emerged as an independent predictor of breast cancer risk. Women with highly dense breasts possess a significantly greater likelihood of developing breast cancer than those with predominantly fatty breast tissue. Increased breast density reflects greater epithelial and stromal tissue content, both of which provide a larger population of susceptible cells for malignant transformation while simultaneously reducing mammographic sensitivity. Furthermore, women with a history of atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or proliferative benign breast disease exhibit a substantially increased risk of future breast cancer development. Boyd et al. (2007) first established breast density as one of the strongest independent imaging biomarkers of breast cancer risk, and subsequent studies continue to support its prognostic significance.

4.6 Gene-Environment Interactions

Current evidence indicates that breast cancer development cannot be attributed to a single etiological factor but rather results from complex interactions between inherited genetic susceptibility and environmental exposures. Genetic polymorphisms affecting hormone metabolism, DNA repair capacity, inflammatory pathways, and carcinogen detoxification may modify an individual's response to lifestyle and environmental risk factors. Consequently, women carrying inherited susceptibility variants may exhibit markedly different disease risks despite similar environmental exposures. Advances in molecular epidemiology and genome-wide association studies have substantially improved understanding of these interactions and are expected to facilitate more accurate individualized risk prediction models in the future (Michailidou et al., 2017).

Overall, breast cancer etiology is highly complex and multifactorial, involving the cumulative effects of inherited susceptibility, endocrine influences, lifestyle behaviors, environmental exposures, aging, and molecular alterations. A comprehensive understanding of these risk factors is essential for developing effective prevention strategies, identifying high-risk populations, implementing personalized screening programs, and advancing precision medicine approaches aimed at reducing the global burden of breast cancer.

5. Molecular Pathogenesis of Breast Cancer

Breast cancer is a genetically and molecularly heterogeneous disease that develops through the progressive accumulation of genetic, epigenetic, and microenvironmental alterations that disrupt normal cellular homeostasis. The transformation of normal mammary epithelial cells into malignant cells is a multistep process involving dysregulation of cell-cycle control, DNA repair mechanisms, apoptosis, cellular metabolism, and signal transduction pathways. These molecular abnormalities collectively promote uncontrolled cellular proliferation, invasion, angiogenesis, immune evasion, and distant metastasis. Recent advances in molecular biology, genomics, and transcriptomics have considerably improved the understanding of breast cancer pathogenesis, facilitating the development of targeted therapies and precision medicine approaches. Xiong et al. (2025) emphasized that breast cancer progression results from dynamic interactions between intrinsic genetic alterations and the surrounding tumor microenvironment, both of which influence tumor initiation, progression, and therapeutic response.

5.1 Initiation of Breast Carcinogenesis

Breast carcinogenesis begins with the accumulation of irreversible genetic and epigenetic alterations within mammary epithelial cells, particularly those located in the terminal ductal-lobular unit (TDLU), the primary site of origin for most breast cancers. These alterations arise from inherited susceptibility, spontaneous mutations during DNA replication, hormonal stimulation, oxidative stress, environmental carcinogens, and aging. Initially, affected cells undergo hyperplasia followed by atypical hyperplasia and carcinoma in situ before progressing to invasive breast carcinoma.

The transition from normal epithelium to invasive malignancy is accompanied by progressive disruption of genomic integrity, increased proliferative capacity, resistance to apoptosis, and loss of normal tissue architecture. Hanahan (2022) described tumor initiation as a consequence of cumulative molecular alterations that enable transformed cells to acquire selective growth advantages over surrounding normal tissues.

5.2 Genetic and Epigenetic Alterations

Genomic instability represents one of the fundamental characteristics of breast cancer. Mutations affecting oncogenes, tumor suppressor genes, and DNA repair genes lead to deregulated cellular proliferation and impaired genomic maintenance. Among hereditary breast cancers, pathogenic variants in BRCA1 and BRCA2 impair homologous recombination-mediated DNA repair, resulting in chromosomal instability and increased mutation frequency. Somatic mutations involving TP53, PIK3CA, GATA3, AKT1, ESR1, and PTEN are frequently identified in sporadic breast cancers and contribute to subtype-specific disease progression. Sokolova et al. (2023) demonstrated that alterations in DNA repair pathways significantly influence both breast cancer susceptibility and response to targeted therapies such as PARP inhibitors.

In addition to genetic mutations, epigenetic modifications including DNA methylation, histone modifications, and dysregulated microRNA expression contribute significantly to breast cancer development. Aberrant promoter hypermethylation frequently silences tumor suppressor genes, whereas global DNA hypomethylation promotes chromosomal instability. Altered expression of oncogenic and tumor-suppressive microRNAs further modulates signaling pathways regulating proliferation, apoptosis, epithelial differentiation, and metastasis. Unlike genetic mutations, epigenetic alterations are potentially reversible, making them attractive therapeutic targets for future breast cancer management.

5.3 Dysregulation of Cell Cycle and Apoptosis

Normal mammary epithelial cells maintain tissue homeostasis through strict regulation of cell-cycle progression and programmed cell death. In breast cancer, this regulatory balance is disrupted by overexpression of cyclins, activation of cyclin-dependent kinases (CDKs), and inactivation of cell-cycle inhibitors, leading to uncontrolled cellular proliferation.

Loss of tumor suppressor proteins such as p53 further compromises DNA damage surveillance by preventing apoptosis of genetically unstable cells. Consequently, cells harboring oncogenic mutations continue to proliferate, accumulate additional genomic abnormalities, and eventually acquire malignant characteristics. Vousden and Lane (2022) reported that dysfunction of the p53 signaling pathway is among the most common molecular events associated with breast cancer progression and therapeutic resistance.

5.4 Major Molecular Signaling Pathways

Multiple intracellular signaling pathways regulate normal mammary gland development and tissue homeostasis. Aberrant activation of these pathways contributes directly to breast cancer initiation, progression, and therapeutic resistance.

5.4.1 PI3K/AKT/mTOR Signaling Pathway

The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR pathway regulates cellular proliferation, metabolism, protein synthesis, angiogenesis, and survival. Activating mutations in PIK3CA, amplification of growth factor receptors, and loss of the tumor suppressor PTEN result in constitutive activation of this pathway, promoting uncontrolled tumor growth and resistance to apoptosis. Persistent activation of PI3K/AKT signaling has been observed in a substantial proportion of hormone receptor-positive breast cancers and represents an important therapeutic target. Miller et al. (2021) highlighted that inhibition of this pathway significantly improves clinical outcomes in selected breast cancer patients.

5.4.2 HER2 Signaling Pathway

Amplification or overexpression of the human epidermal growth factor receptor-2 (HER2) gene occurs in approximately 15-20% of breast cancers and is associated with rapid tumor growth, increased metastatic potential, and poor clinical prognosis. Activation of HER2 stimulates multiple downstream signaling cascades, including PI3K/AKT and MAPK pathways, resulting in enhanced proliferation, angiogenesis, and inhibition of apoptosis. The introduction of HER2-targeted therapies has substantially improved survival among patients with HER2-positive disease. Moasser (2024) emphasized that HER2 remains one of the most clinically significant predictive biomarkers in breast oncology.

5.4.3 MAPK Signaling Pathway

The mitogen-activated protein kinase (MAPK) signaling cascade regulates cellular differentiation, proliferation, migration, and survival. Persistent activation of receptor tyrosine kinases or downstream signaling molecules enhances transcription of genes promoting cell-cycle progression and tumor growth. Crosstalk between MAPK and PI3K signaling contributes to treatment resistance and disease progression, particularly in advanced breast cancer.

5.4.4 Estrogen Receptor Signaling

Approximately two-thirds of breast cancers express estrogen receptors and depend on estrogen-mediated signaling for cellular proliferation. Binding of estrogen to estrogen receptor-α activates transcription of genes regulating cell-cycle progression, proliferation, and survival. Dysregulated estrogen receptor signaling not only promotes tumor growth but also contributes to endocrine resistance following prolonged hormonal therapy. Understanding this pathway has facilitated the development of selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders that constitute the cornerstone of endocrine therapy.

5.5 Tumor Microenvironment

Breast cancer progression is profoundly influenced by reciprocal interactions between malignant epithelial cells and the surrounding tumor microenvironment. This specialized microenvironment comprises cancer-associated fibroblasts, immune cells, endothelial cells, adipocytes, extracellular matrix proteins, cytokines, and chemokines that collectively regulate tumor behavior.

Cancer-associated fibroblasts stimulate extracellular matrix remodeling, angiogenesis, and epithelial-mesenchymal transition, thereby facilitating local invasion and metastatic dissemination. Tumor-associated macrophages promote chronic inflammation and suppress anti-tumor immune responses through secretion of immunosuppressive cytokines. Furthermore, extracellular matrix remodeling alters tissue stiffness and promotes cancer cell migration. Balkwill and Mantovani (2022) reported that chronic inflammation within the tumor microenvironment represents a major driver of breast cancer progression and metastatic spread.

5.6 Angiogenesis and Metastatic Progression

Tumor growth beyond a few millimeters requires the formation of new blood vessels through angiogenesis. Hypoxia within rapidly proliferating tumors stimulates expression of vascular endothelial growth factor (VEGF) and other proangiogenic mediators, promoting vascularization and nutrient supply. Newly formed tumor vasculature is structurally abnormal and facilitates intravasation of cancer cells into the circulation.

Metastasis involves a complex sequence of events including local invasion, epithelial-mesenchymal transition (EMT), intravasation, survival within the circulation, extravasation, and colonization of distant organs. Breast cancer most commonly metastasizes to bone, lung, liver, and brain. Molecular regulators including E-cadherin, matrix metalloproteinases (MMPs), transforming growth factor-β, and EMT-associated transcription factors facilitate metastatic dissemination. Lambert et al. (2017) described metastasis as the principal cause of breast cancer-related mortality and one of the greatest challenges in clinical oncology.

5.7 Molecular Heterogeneity and Therapeutic Implications

One of the defining characteristics of breast cancer is its remarkable molecular heterogeneity. Distinct genetic alterations, signaling pathway activation, and tumor microenvironmental interactions produce biologically diverse tumors that differ substantially in prognosis and treatment response. Molecular profiling technologies have enabled classification of breast cancer into clinically relevant intrinsic subtypes, thereby facilitating individualized treatment strategies.

Identification of actionable molecular targets has accelerated the development of targeted therapies, immunotherapies, antibody-drug conjugates, and precision medicine approaches that continue to transform breast cancer management. Continued integration of genomics, transcriptomics, proteomics, and single-cell sequencing is expected to further refine molecular classification and improve personalized therapeutic interventions.

Diagnosis

Accurate and timely diagnosis is essential for improving the clinical outcomes of patients with breast cancer, as early detection significantly increases treatment success and overall survival. The diagnostic approach has evolved considerably over the past few decades with the integration of advanced imaging technologies, histopathological evaluation, immunohistochemistry, molecular diagnostics, and genomic profiling. Rather than relying on a single investigation, the diagnosis of breast cancer requires a multidisciplinary approach that combines clinical assessment with radiological and pathological findings to accurately characterize the tumor and determine its biological behavior. This comprehensive evaluation not only confirms the presence of malignancy but also provides critical information regarding tumor subtype, stage, receptor status, and genetic alterations, all of which are essential for selecting the most appropriate therapeutic strategy. Mann et al. (2019) emphasized that combining clinical examination, imaging modalities, and tissue biopsy substantially improves diagnostic accuracy while reducing unnecessary interventions. Similarly, Gradishar et al. (2024) highlighted that modern breast cancer diagnosis extends beyond identifying the primary lesion to include molecular characterization and biomarker assessment, which have become integral components of precision oncology. Recent advances in artificial intelligence, radiomics, liquid biopsy, and next-generation sequencing are further transforming breast cancer diagnosis by enabling earlier detection, real-time disease monitoring, and individualized treatment planning. Consequently, the integration of conventional diagnostic techniques with emerging molecular technologies has significantly enhanced the ability to detect breast cancer at earlier stages, improve prognostic assessment, and optimize personalized patient management.

6. Biomarkers in Breast Cancer

Biomarkers play a pivotal role in the diagnosis, prognosis, therapeutic decision-making, and disease monitoring of breast cancer. They provide valuable information regarding tumor biology, molecular heterogeneity, treatment responsiveness, and clinical outcomes, thereby facilitating the implementation of precision oncology. The rapid advancement of molecular diagnostics has led to the identification of numerous prognostic and predictive biomarkers that enable individualized treatment strategies and improve patient survival. Biomarkers can be detected in tumor tissue, blood, or other biological fluids and are broadly classified into diagnostic, prognostic, predictive, and pharmacodynamic biomarkers based on their clinical applications. Turner et al. (2020) emphasized that integrating biomarker profiling into routine clinical practice has transformed breast cancer management by enabling more accurate risk stratification and personalized therapeutic interventions. Furthermore, the incorporation of genomic assays and liquid biopsy technologies has expanded the scope of biomarker-guided precision medicine, allowing clinicians to monitor disease progression and therapeutic response more effectively.

6.1 Hormone Receptors

Hormone receptor status remains one of the most important predictive biomarkers in breast cancer. Estrogen receptor (ER) and progesterone receptor (PR) expression are routinely evaluated using immunohistochemistry because they provide essential information regarding tumor biology and endocrine responsiveness. Approximately 70% of breast cancers express ER, making endocrine therapy a cornerstone of treatment for these patients. ER-positive tumors generally exhibit slower growth rates, lower recurrence risk, and better long-term prognosis than hormone receptor-negative tumors.

Progesterone receptor expression is largely regulated by estrogen signaling and serves as an indicator of functional estrogen receptor activity. Simultaneous assessment of ER and PR status improves prognostic accuracy and assists clinicians in selecting endocrine therapies such as tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders. According to Allison et al. (2020), standardized assessment of hormone receptor expression remains essential for optimizing treatment selection and predicting clinical outcomes.

6.2 Human Epidermal Growth Factor Receptor-2 (HER2)

Human epidermal growth factor receptor-2 (HER2) is a transmembrane receptor tyrosine kinase encoded by the ERBB2 gene. Amplification or overexpression of HER2 occurs in approximately 15-20% of invasive breast cancers and is associated with aggressive tumor behavior, increased metastatic potential, and poor prognosis if left untreated.

HER2 status is routinely determined using immunohistochemistry, while equivocal cases require confirmation through fluorescence in situ hybridization (FISH) or in situ hybridization techniques to assess gene amplification. The identification of HER2 overexpression has dramatically improved patient outcomes because it enables the use of targeted therapies including trastuzumab, pertuzumab, trastuzumab emtansine, and trastuzumab deruxtecan. Wolff et al. (2023) recommended standardized HER2 testing to ensure accurate patient selection for HER2-directed therapies.

6.3 Ki-67 Proliferation Index

Ki-67 is a nuclear protein expressed during active phases of the cell cycle and serves as an important marker of cellular proliferation. High Ki-67 expression is generally associated with rapid tumor growth, increased histological grade, and unfavorable clinical outcomes. Measurement of the Ki-67 labeling index assists in differentiating Luminal A from Luminal B breast cancers and provides additional prognostic information beyond conventional histopathological parameters.

Although variability in laboratory methodologies has limited universal standardization, Ki-67 remains widely used for estimating proliferative activity and guiding treatment decisions, particularly in hormone receptor-positive early breast cancer. Dowsett et al. (2019) highlighted that Ki-67 assessment contributes significantly to prognostic evaluation when interpreted alongside other clinicopathological parameters.

6.4 Germline and Somatic Genetic Biomarkers

Genetic biomarkers have become increasingly important in breast cancer risk assessment and targeted therapy. Germline mutations in BRCA1, BRCA2, PALB2, TP53, ATM, and CHEK2 significantly increase susceptibility to hereditary breast cancer by impairing DNA repair mechanisms. Identification of these mutations supports genetic counseling, individualized surveillance strategies, and selection of targeted therapies such as PARP inhibitors.

Somatic mutations also contribute to breast cancer progression and therapeutic response. Alterations in PIK3CA, ESR1, AKT1, and PTEN influence multiple intracellular signaling pathways regulating cellular proliferation and endocrine resistance. Detection of PIK3CA mutations has particular therapeutic relevance because patients harboring these alterations may benefit from PI3K inhibitors such as alpelisib. Sokolova et al. (2023) emphasized that comprehensive genomic testing has become an integral component of precision oncology for breast cancer.

Table 1: Current Therapeutic Approaches for Breast Cancer

7. Emerging Therapies in Breast Cancer

The treatment landscape of breast cancer has evolved remarkably over the past decade with the emergence of innovative therapeutic strategies that extend beyond conventional surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted agents. Advances in molecular oncology, genomics, immunology, and nanotechnology have accelerated the development of novel therapies aimed at improving treatment efficacy while minimizing systemic toxicity. Unlike traditional treatment approaches, emerging therapies focus on specific molecular abnormalities, immune modulation, personalized medicine, and advanced drug delivery systems to overcome therapeutic resistance and improve long-term clinical outcomes. These therapeutic innovations have demonstrated promising results, particularly in patients with metastatic disease, triple-negative breast cancer (TNBC), and treatment-resistant tumors. Loibl et al. (2021) emphasized that the integration of molecular profiling with innovative therapeutics is transforming breast cancer management from a standardized approach toward individualized precision oncology.

7.1 Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) represent one of the most significant recent advances in breast cancer therapy. These targeted therapeutics combine highly specific monoclonal antibodies with potent cytotoxic agents through specialized chemical linkers, allowing selective delivery of chemotherapy directly to tumor cells while minimizing systemic toxicity. Upon binding to tumor-associated antigens such as HER2 or Trop-2, the ADC is internalized, releasing the cytotoxic payload within malignant cells and inducing apoptosis.

Several ADCs have demonstrated remarkable clinical efficacy in advanced breast cancer. Trastuzumab deruxtecan (T-DXd) has significantly improved progression-free and overall survival in HER2-positive and HER2-low metastatic breast cancer, while Sacituzumab govitecan, targeting Trop-2, has shown substantial benefits in metastatic TNBC. These agents have expanded therapeutic options for patients with heavily pretreated disease and are increasingly being incorporated into clinical practice. Modi et al. (2022) reported that ADCs represent a paradigm shift in targeted breast cancer therapy because they combine the specificity of immunotherapy with the cytotoxic potency of chemotherapy.

7.2 Immunotherapy

Immunotherapy has emerged as an important therapeutic strategy, particularly for triple-negative breast cancer, which exhibits limited responsiveness to endocrine and HER2-targeted therapies. Immune checkpoint inhibitors restore antitumor immunity by blocking inhibitory signaling pathways that suppress T-cell activation. Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1), including Pembrolizumab and Atezolizumab, have demonstrated improved survival when combined with chemotherapy in patients with PD-L1-positive TNBC.

In addition to immune checkpoint blockade, several immunotherapeutic strategies including cancer vaccines, adoptive T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and cytokine-based immunotherapy are currently under clinical investigation. Although immunotherapy has produced durable responses in selected patient populations, challenges such as immune-related adverse events, biomarker identification, and therapeutic resistance continue to limit broader clinical application. Schmid et al. (2022) concluded that immunotherapy is expected to become an increasingly important component of combination treatment strategies for aggressive breast cancer subtypes.

7.3 PARP Inhibitors and Synthetic Lethality

The discovery of defects in homologous recombination repair pathways has led to the successful development of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with germline BRCA1 and BRCA2 mutations. PARP inhibitors exploit the concept of synthetic lethality by selectively targeting tumor cells with impaired DNA repair capacity while sparing normal cells.

Currently approved agents such as Olaparib and Talazoparib have demonstrated significant improvements in progression-free survival among patients with HER2-negative metastatic breast cancer harboring germline BRCA mutations. Ongoing clinical trials are investigating combinations of PARP inhibitors with immunotherapy, chemotherapy, and targeted therapies to further enhance clinical efficacy. Tung et al. (2020) highlighted that PARP inhibition represents one of the earliest successful examples of biomarker-driven precision oncology in breast cancer.

7.4 Cellular and Gene-Based Therapies

Cellular immunotherapy is an emerging area of breast cancer research aimed at enhancing the patient's immune system to recognize and eliminate malignant cells. Among these approaches, chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated remarkable success in hematological malignancies and is currently being investigated for solid tumors, including breast cancer. Researchers are evaluating novel tumor-associated antigens such as HER2, MUC1, mesothelin, and receptor tyrosine kinase-like orphan receptor-1 (ROR1) as potential CAR-T targets.

Gene-editing technologies, particularly CRISPR-Cas9, have also generated considerable interest because of their ability to selectively modify cancer-associated genes involved in tumor growth, metastasis, and drug resistance. Although these approaches remain largely experimental, they hold significant promise for future precision medicine applications. Doudna and Charpentier (2022) emphasized that gene-editing technologies have the potential to revolutionize cancer therapy through highly specific genomic modifications.

7.5 Nanotechnology Based Therapeutics

Nanotechnology has become an important area of breast cancer research owing to its ability to improve drug delivery, enhance therapeutic efficacy, and reduce systemic toxicity. Nanocarriers including liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, micelles, and lipid-polymer hybrid nanoparticles enable controlled drug release, prolonged circulation time, enhanced tumor accumulation through the enhanced permeability and retention (EPR) effect, and active targeting using tumor-specific ligands.

Several nanomedicine formulations have already entered clinical practice, while numerous investigational nanoparticle-based systems are being evaluated for the targeted delivery of chemotherapeutic agents, small interfering RNA (siRNA), messenger RNA (mRNA), proteins, and CRISPR gene-editing systems. Recent developments in multifunctional nanoplatforms capable of simultaneous diagnosis and therapy (theranostics) are expected to further improve breast cancer management. Shi et al. (2023) reported that nanotechnology is becoming an essential component of next-generation precision oncology.

7.6 Artificial Intelligence and Precision Oncology

Artificial intelligence (AI) is increasingly being integrated into breast cancer diagnosis, prognosis, treatment planning, and therapeutic monitoring. Machine learning and deep learning algorithms facilitate automated interpretation of mammographic images, digital pathology slides, genomic data, and radiological features, thereby improving diagnostic accuracy and reducing observer variability.

The integration of AI with molecular profiling supports precision oncology by predicting treatment response, identifying novel therapeutic targets, and optimizing individualized treatment selection. AI-assisted clinical decision support systems are also being developed to integrate clinical, pathological, radiological, and genomic information into comprehensive predictive models that improve personalized patient care. Esteva et al. (2021) suggested that artificial intelligence will become an indispensable component of future breast cancer management.

7.7 Future Perspectives

The future of breast cancer therapy is increasingly focused on combining multiple targeted approaches to overcome tumor heterogeneity and therapeutic resistance. Combination strategies integrating immunotherapy, targeted therapy, antibody-drug conjugates, nanomedicine, and molecular diagnostics are expected to further improve patient outcomes. Emerging technologies including single-cell sequencing, spatial transcriptomics, liquid biopsy, organoid models, and multi-omics profiling are providing unprecedented insights into tumor biology and facilitating the discovery of novel therapeutic targets. Continued advances in personalized medicine, supported by artificial intelligence and biomarker-guided treatment selection, are anticipated to reshape the clinical management of breast cancer and significantly improve long-term survival.

Overall, emerging therapies represent a new era in breast cancer management by shifting the focus from generalized treatment protocols toward individualized therapeutic interventions tailored to the unique molecular characteristics of each patient's tumor. Continued translational research, well-designed clinical trials, and integration of precision medicine into routine clinical practice will be essential for maximizing the clinical benefits of these innovative therapeutic approaches.

8. Conclusion

Over the past few decades, there have been significant advancements in the knowledge and treatment of breast cancer, a complicated and diverse illness. The transition from a single disease entity to several different subtypes has made it possible to develop individualized treatment plans that have greatly enhanced patient outcomes. Reducing gaps in care access and outcomes, treating metastatic illness, and tackling treatment resistance are some of the current problems. Immunotherapy, antibody-drug conjugates, and precision medicine techniques are examples of emerging treatment methods that show potential for further enhancing patient outcomes.

Increasingly individualized methods based on thorough genetic characterisation, real-time monitoring via liquid biopsies, and the incorporation of artificial intelligence to maximize therapy choice and timing are probably in store for the future of breast cancer care. Translating these developments into better outcomes for all breast cancer patients would need sustained research efforts, international cooperation, and a dedication to resolving healthcare inequities. For the best possible patient care, the multidisciplinary approach to breast cancer treatment which includes surgery, medical oncology, radiation oncology, pathology, radiology, and supportive care services—will continue to be essential. The establishment of guidelines, continuous education, and modifications to the healthcare system will be necessary to incorporate new knowledge into clinical practice as our understanding of breast cancer biology advances.

9. Acknowledgements

The authors would like to express their sincere gratitude to all the researchers and institutions whose work has contributed to the development of this review. 

10. Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this review.

11. References

• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Arch Pathol Lab Med. 2020;144(5):545-563. 
• Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816-1837. 
• Balkwill FR, Mantovani A. Cancer-related inflammation: common pathways and therapeutic opportunities. Nat Rev Cancer. 2022;22:85-97. 
• Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3):320-329. 
• Bonkhoff AK, Grefkes C. Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. Brain. 2022;145(2):457-475. 
• Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236. 
• Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024.
• Brisken C, Ataca D. Endocrine hormones and local signals during mammary gland development. Wiley Interdiscip Rev Dev Biol. 2015;4(3):181-195. 
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220. 
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis. Lancet. 2019;394:1159-1168. 
• Debien V, De Caluwé A, Wang X, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. npj Breast Cancer. 2023;9:7. 
• Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2022;346(6213):1258096. 
• Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki-67 in breast cancer: recommendations from the International Ki67 Working Group. J Natl Cancer Inst. 2019;111(10):1015-1025. 
• Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2021;27(1):24-29. 
• Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024.
• Fu NY, Nolan E, Lindeman GJ, Visvader JE. Stem cells and the differentiation hierarchy in the mammary gland. Nat Rev Mol Cell Biol. 2023;24:569-587. 
• Giuliano AE, et al. Axillary staging and sentinel lymph node biopsy in breast cancer: current perspectives. Ann Surg Oncol. 2023.
• Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. J Natl Compr Canc Netw. 2024;22(5):331-419. 
• Gradishar WJ, Moran MS, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. J Natl Compr Canc Netw. 2024;22(5):331-419. 
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. 
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. 
• Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8:e1027-e1037.
• Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022;42(10):913-936. doi:10.1002/cac2.12358. 
• Huppert LA, et al. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early-stage and metastatic breast cancer. CA Cancer J Clin. 2023;73(5):480-515. doi:10.3322/caac.21792. 
• Huppert LA, Rastogi P, Rugo HS, et al. Systemic therapy for hormone receptor-positive/HER2-negative early-stage and metastatic breast cancer. CA Cancer J Clin. 2023;73(5):480-515.
• Ignatiadis M, Sledge GW Jr, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297-312. 
• Ignatiadis M, Sledge GW Jr, Jeffrey SS. Liquid biopsy enters the clinic: implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297-312. 
• Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670-691.
• Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798. 
• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry study. J Hematol Oncol. 2021;14:1-14.
• Li J, Yang Y, Peng Y, et al. Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Mol Biomed. 2025;6(1):111. 
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0.
• Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-1769. 
• Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol. 2012;1(4):533-557. 
• Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-295.
• Mann RM, Athanasiou A, Baltzer PAT, Camps-Herrero J, Clauser P, Fallenberg EM, et al. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2019;29(3):1436-1449. doi:10.1007/s00330-018-5666-z. 
• Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies new breast cancer susceptibility loci. Nature. 2017;551:92-94.
• Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and AKT signaling in breast cancer. Clin Cancer Res. 2021;27:357-369. 
• Moasser MM. HER2-targeted therapy in breast cancer: current status and future directions. Nat Rev Clin Oncol. 2024. 
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. 
• Molla G, Bitew M. The future of cancer diagnosis and treatment: unlocking the power of biomarkers and personalized molecular-targeted therapies. J Mol Pathol. 2025;6(3):20. 
• Morris PG, et al. Antibody-drug conjugates in breast cancer: ascent to destiny and beyond. Cancers (Basel). 2023;15:3905. 
• Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor revolution—a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21:89-105. 
• Popa MT, Bădulescu F, Georgescu TA, et al. Breast cancer: a heterogeneous pathology—prognostic and predictive factors: A narrative review. Chirurgia (Bucur). 2025;120(1):32-47. 
• Predieri B, Iughetti L, Guerranti C, et al. Endocrine-disrupting chemicals' effects in children: what we know and what we need to learn. Int J Mol Sci. 2022;23(19):11899. 
• References
• Rusby JE, et al. Anatomy and morphology of the human breast. Surg Oncol Clin N Am. 2020;29(1):1-16. 
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556-567. 
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2023;23(6):321-340. 
• Sokolova A, Murphy CG, Garber JE, et al. Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology. 2023;82(1):70-82. 
• Sokolova A, Murphy CG, Garber JE, et al. Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology. 2023;82(1):70-82. 
• Sokolova A, Murphy CG, Garber JE, et al. Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology. 2023;82(1):70-82. 
• Subhan MA, Rahman MM, Hossain MS, et al. Recent advances with precision medicine treatment for breast cancer including triple-negative subtype. Cancers (Basel). 2023;15(8):2204. doi:10.3390/cancers15082204. 
• Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020;38(18):2080-2106. 
• Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: ASCO, ASTRO, and SSO guideline. J Clin Oncol. 2020;38(18):2080-2106. 
• Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: ASCO, ASTRO, and SSO guideline. J Clin Oncol. 2020;38(18):2080-2106. 
• Turner NC, Kingston B, Kilburn LS, et al. Biomarker-driven treatment strategies in breast cancer. Nat Rev Clin Oncol. 2020;17(12):725-741. 
• Visvader JE. Cells of origin in cancer. Nature. 2011;469(7330):314-322. 
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2022;23:393-408. 
• Wang J, Wu SG. Breast cancer: an overview of current therapeutic strategies, challenges, and perspectives. Breast Cancer (Dove Med Press). 2023;15:721-730. doi:10.2147/BCTT.S438465. 
• Wang J, Wu SG. Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer (Dove Med Press). 2023;15:721-730. 
• Wang Y, Minden A. Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci. 2022;23(19):11046. doi:10.3390/ijms231911046. 
• Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. doi:10.1259/bjr.20211033. 
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2023;41(22):3867-3872. 
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2023;41(22):3867-3872. 
• Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2023;41(22):3867-3872. 
• World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Breast Cancer. Continuous Update Project Expert Report. London: WCRF; 2018.
• Xiong X, Xu X, Wang X, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. doi:10.1038/s41392-025-02170-2. 
• Xiong X, Xu X, Wang X, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49.